Synergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical...
Thursday, December 27, 2012, 2:09 PM ETSynergy Pharmaceuticals (SGYP +5.3%) moves up after saying its commenced Phase IIb clinical trials of plecanatide, a treatment for patients with constipation-predominant irritable bowel syndrome. The trial is being conducted at 70 sites in the U.S. and includes 350 patients. Parexel International (PRXL -2%) is the contract research organization for the trial.
HEALTHCARE ETFs IN FOCUS
Latest Healthcare Articles